Viridian Therapeutics Files 8-K on Financials
Ticker: VRDN · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1590750
Sentiment: neutral
Topics: financials, filing
TL;DR
Viridian Therapeutics dropped an 8-K on Aug 8th covering financials. Check it out.
AI Summary
Viridian Therapeutics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing provides crucial updates on Viridian Therapeutics' financial health and operational status, which is important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant risk disclosures.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- August 8, 2024 (date) — Date of earliest event reported
- Miragen Therapeutics, Inc. (company) — Former company name
- Signal Genetics, Inc. (company) — Former company name
- Waltham, MA (location) — Company headquarters
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on August 8, 2024.
What were Viridian Therapeutics' previous names?
Viridian Therapeutics was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
Where is Viridian Therapeutics, Inc. incorporated?
The company is incorporated in Delaware.
What is the business address of Viridian Therapeutics, Inc.?
The business address is 221 Crescent Street, Suite 103A, Waltham, MA 02453.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-08-08 08:25:01
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
Filing Documents
- d879446d8k.htm (8-K) — 25KB
- d879446dex991.htm (EX-99.1) — 68KB
- g879446g0803101051372.jpg (GRAPHIC) — 3KB
- g879446g0805155158890.jpg (GRAPHIC) — 2KB
- 0001193125-24-196513.txt ( ) — 235KB
- vrdn-20240808.xsd (EX-101.SCH) — 3KB
- vrdn-20240808_lab.xml (EX-101.LAB) — 18KB
- vrdn-20240808_pre.xml (EX-101.PRE) — 11KB
- d879446d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits . Exhibit Number Exhibit Description 99.1 Press release, dated August 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: August 8, 2024 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director